GFS Advisors’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

GFS Advisors’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$475	Buy	15,222 +1,349	+10%	+$182K	﹤0.01%	263
2026 Q1	$1.77M	Sell	13,873 -2,894	-17%	-$361K	0.23%	71
2025 Q4	$2.04M	Sell	16,767 -405	-2%	-$46.4K	0.24%	71
2025 Q3	$1.72M	Buy	17,172 +1,078	+7%	+$97.1K	0.22%	73
2025 Q2	$1.33M	Hold	16,094	–	–	0.18%	80
2025 Q1	$1.3M	Sell	16,094 -1,612	-9%	-$144K	0.26%	64
2024 Q4	$1.59M	Sell	17,706 -1,251	-7%	-$121K	0.24%	68
2024 Q3	$1.87M	Buy	18,957 +17,617	+1,315%	+$1.73M	0.4%	45
2024 Q2	$1.78M	Sell	1,340 -16,842	-93%	-$1.51M	0.29%	65
2024 Q1	$1.73M	Buy	18,182 +5,738	+46%	+$532K	0.29%	67
2023 Q4	$1.11M	Sell	12,444 -270	-2%	-$20.1K	0.16%	87
2023 Q3	$928K	Sell	12,714 -91	-0.7%	-$7.27K	0.14%	92
2023 Q2	$1.06M	Buy	12,805 +4	+0%	+$335	0.24%	73
2023 Q1	$976K	Sell	12,801 -125	-1%	-$10.4K	0.22%	78
2022 Q4	$1.07M	Buy	12,926 +21	+0.2%	+$1.7K	0.24%	72
2022 Q3	$1.02M	Sell	12,905 -108	-0.8%	-$9.11K	0.25%	73
2022 Q2	$966K	Sell	13,013 -1,802	-12%	-$135K	0.22%	75
2022 Q1	$1.33M	Buy	14,815 +2,434	+20%	+$225K	0.28%	69
2021 Q4	$1.39M	Buy	12,381 +494	+4%	+$59.6K	0.23%	77
2021 Q3	$1.49M	Buy	11,887 +1,811	+18%	+$233K	0.32%	67
2021 Q2	$1.36M	Buy	10,076 +1,741	+21%	+$229K	0.31%	69
2021 Q1	$1.13M	Buy	8,335 +1,459	+21%	+$218K	0.26%	66
2020 Q4	$968K	Buy	6,876 +831	+14%	+$106K	0.25%	72
2020 Q3	$674K	Buy	+6,045	New	+$678K	0.21%	71

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

GFS Advisors's XBI Position: Q2 2026 in Review

GFS Advisors increased its State Street SPDR S&P Biotech ETF (XBI) stake by 9.7% in Q2 2026, buying an estimated $182K and bringing the position to 15,222 shares worth $475. The position accounts for ﹤0.01% of the portfolio, ranked #263.

GFS Advisors first reported a position in XBI in Q3 2020 and has held it in 24 quarters since. The position peaked at $2.04M in Q4 2025. 933 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

GFS Advisors held 15,222 shares of State Street SPDR S&P Biotech ETF worth $475 as of Q2 2026.
GFS Advisors bought 1,349 State Street SPDR S&P Biotech ETF shares in Q2 2026, an estimated $182K.
State Street SPDR S&P Biotech ETF made up ﹤0.01% of GFS Advisors's portfolio in Q2 2026, its #263 holding.
GFS Advisors first reported a position in State Street SPDR S&P Biotech ETF in Q3 2020 and has held it in 24 quarters since.
GFS Advisors's State Street SPDR S&P Biotech ETF position peaked at $2.04M in Q4 2025.
933 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on GFS Advisors's 13F filing for Q2 2026, filed 4 Aug 2026.